Yayın:
Design and evaluation of peptide-18-targeted nanoliposomes constructed by poly(2-oxazoline)-DOPE for doxorubicin delivery

Basit öğe sayfası
dc.contributor.authorDevrim, Burcu
dc.contributor.authorBolat, Zeynep Busra
dc.contributor.authorTelci, Dilek
dc.contributor.authorŞahin, Fikrettin
dc.contributor.authorGulyuz, Sevgi
dc.contributor.authorOzkose, Umut Ugur
dc.contributor.authorYilmaz, Ozgur
dc.contributor.authorBozkır, Asuman
dc.date.accessioned2026-01-25T04:02:14Z
dc.date.issued2021-04-14
dc.description.abstractThe aim of this study is to develop targeted nanoliposome formulations to provide efficient treatment for breast cancer. In this study, peptide 18-modified poly(2-ethyl-2-oxazoline)-dioleoylphosphatidylethanolamine (P18-PEtOx-DOPE), was synthesised to construct nanoliposomes.Doxorubicin (DOX) was encapsulated into the nanoliposomes by ethanol injection method. Particle size and polydispersity index were measured by dynamic light scattering. Zeta potential was determined by electrophoretic laser Doppler anemometry. The shape of the nanoliposomes was examined by transmission electron microscope. Specific bindings of P18-PEtOx-DOPE nanoliposomes were demonstrated on AU565 cells by confocal microscopy and flow cytometry studies.DOX-loaded nanoliposomes with particle diameter of 150.00 ± 2.84 nm and PDI of 0.212 ± 0.013 were obtained. PEtOx-DOPE and PEtOx-DOPE nanoliposomes are non-toxic on HUVEC, HEK293 and hMSC cells for 48 h. Furthermore, P18-PEtOx-DOPE nanoliposomes demonstrated specificity towards AU565 cells with high binding affinity.As a result, DOX-loaded P18-PEtOx-DOPE nanoliposomes can serve as favourable candidates in breast cancer targeted therapy.
dc.description.urihttps://doi.org/10.1080/02652048.2021.1905094
dc.description.urihttps://pubmed.ncbi.nlm.nih.gov/33853478
dc.description.urihttps://dx.doi.org/10.1080/02652048.2021.1905094
dc.description.urihttps://hdl.handle.net/20.500.12436/3149
dc.description.urihttps://aperta.ulakbim.gov.tr/record/229558
dc.identifier.doi10.1080/02652048.2021.1905094
dc.identifier.eissn1464-5246
dc.identifier.endpage297
dc.identifier.issn0265-2048
dc.identifier.openairedoi_dedup___::5cfdf3a29ab381bcf14226977d5ec3df
dc.identifier.orcid0000-0002-2793-6533
dc.identifier.orcid0000-0003-1503-5567
dc.identifier.orcid0000-0002-2576-3085
dc.identifier.orcid0000-0003-4807-6322
dc.identifier.orcid0000-0003-3892-2775
dc.identifier.startpage285
dc.identifier.urihttps://hdl.handle.net/11527/44819
dc.identifier.volume38
dc.language.isoeng
dc.publisherInforma UK Limited
dc.relation.ispartofJournal of Microencapsulation
dc.rightsOPEN
dc.sdg.typeGoal 3: Good Health and Well-being
dc.subjectMyocytes, Smooth Muscle
dc.subjectPEtOx
dc.subjectBreast Neoplasms
dc.subjectpeptide 18
dc.subjectbreast cancer
dc.subjectDrug Delivery Systems
dc.subjectDrug Stability
dc.subjectCell Line, Tumor
dc.subjectHuman Umbilical Vein Endothelial Cells
dc.subjectHumans
dc.subjectScattering, Radiation
dc.subjectParticle Size
dc.subjectOxazoles
dc.subjectAntibiotics, Antineoplastic
dc.subjectPhosphatidylethanolamines
dc.subjecttargeted therapy
dc.subjectHEK293 Cells
dc.subjectDoxorubicin
dc.subjectDrug Design
dc.subjectLiposomes
dc.subjectNanoparticles
dc.subjectFemale
dc.subjectDrug Screening Assays, Antitumor
dc.subjectPeptides
dc.subjectNanoliposome
dc.titleDesign and evaluation of peptide-18-targeted nanoliposomes constructed by poly(2-oxazoline)-DOPE for doxorubicin delivery
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyonlar

Yayınlar